21.09.2022 • News

Roquette Acquires Indian Excipient Manufacturer

Roquette, a French-based provider of pharmaceutical and nutraceutical excipients, has acquired Crest Cellulose, an Indian excipient manufacturer, reinforcing its presence in India and Asia.

© Roquette
© Roquette

The move follows Roquette’s purchase of a majority stake in Crest Cellulose from Indian pharma packaging company Pravesha Industries in December 2018. A privately owned company based in Mumbai, Crest Cellulose has locations in Hyderabad and Nellore, manufacturing a wide range of “superior” excipients.

“The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia and the rest of the world,” said Paul Smaltz, vice president at Roquette Pharma Solutions.

According to Roquette, India’s pharma industry is poised for a period of seismic growth and production of generics in the Asia-Pacific region is also expanding.  

Author: Elaine Burridge, Freelance Journalist

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read